[Adjuvant chemotherapy].
Copyright policy )[Adjuvant chemotherapy].
The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by Medtronic Synchromed implantable pump in 14-day cycles alternating with 14-day intervals of physiologic saline infusion. Of the patient observed for at least 8 months (range: 8-32, median: 22.1) 1 showed progression. Circadian continuous central venous infusion of FUDR is minimally toxic. The FUDR can be delivered safely and conveniently in this way for long spans. This therapy is administrated in on entirely out patient setting, and associated with a normal quality of life.
- University of Milan Italy
Adult, Time Factors, Humans, Infusion Pumps, Implantable, Middle Aged, Floxuridine, Infusions, Intravenous, Carcinoma, Renal Cell, Drug Administration Schedule, Kidney Neoplasms, Aged, Follow-Up Studies
Adult, Time Factors, Humans, Infusion Pumps, Implantable, Middle Aged, Floxuridine, Infusions, Intravenous, Carcinoma, Renal Cell, Drug Administration Schedule, Kidney Neoplasms, Aged, Follow-Up Studies
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!